Chelsea Therapeutics To Present At The 2013 Wedbush Life Sciences Management Access Conference

CHARLOTTE, N.C., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 2013 Wedbush Life Sciences Management Access Conference at 10:20 AM on Wednesday, August 14, 2013 at Le Parker Meridien hotel in New York.

Joseph G. Oliveto, Interim Chief Executive Officer will provide a corporate update and an overview of the Northera™ (droxidopa) development program.

Mr. Oliveto's presentation will be webcast live and archived for 30 days on Chelsea's website, www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure. For more information about the Company, visit www.chelseatherapeutics.com .
CONTACT: Investors:         Fara Berkowitz/Susan Kim         Argot Partners         212-600-1902         fara@argotpartners.com         susan@argotpartners.com                  Media:         David Pitts         Argot Partners         212-600-1902         david@argotpartners.com

Chelsea Therapeutics Logo

If you liked this article you might like

Lundbeck to Buy Chelsea Therapeutics for $658M

Lundbeck to Buy Chelsea Therapeutics for $658M

Why Chelsea Therapeutics (CHTP) Stock Is Soaring Today

Why Chelsea Therapeutics (CHTP) Stock Is Soaring Today

Chelsea Exits in Victory With Lundbeck Takeout

Chelsea Exits in Victory With Lundbeck Takeout

Chelsea Therapeutics International Ltd. (CHTP) Shares Soar 14%

Chelsea Therapeutics International Ltd. (CHTP) Shares Soar 14%

'Mad Money' Lightning Round: Zynga Can Go Higher

'Mad Money' Lightning Round: Zynga Can Go Higher